Greg Mayes, Reunion Neuroscience CEO
A once-public psychedelic biotech reemerges with $103M from MPM and Novo Holdings
MPM BioImpact and Novo Holdings are among a group of investors pouring $103 million into a psychedelic biotech that MPM took private last summer. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
